PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v10i3.15162ArticleClinical Review on Perioperative Immunotherapy Patterns for Non-Small Cell Lung Cancerhttps://artdesignp.com/journal/PAR/10/3/10.26689/par.v10i3.15162DongShaoyong,SunJing,YangYing20261032026-05-31The application scope of immunotherapy has gradually expanded from advanced non-small cell lung cancer to the perioperative stage, with three core clinical application forms progressively established: neoadjuvant therapy, adjuvant therapy, and comprehensive management combining neoadjuvant and adjuvant approaches. Recent clinical studies have demonstrated that all three treatment modalities can achieve improvements in pathological response and event-free survival. However, consensus remains elusive regarding the characteristics of beneficiary populations, efficacy differences among various treatment strategies, and perioperative-specific safety risks. By integrating recent clinical research findings and systematically reviewing evidence-based data for each therapeutic approach, this review aims to provide evidence-based support for rational clinical treatment selection.

Wang C, Yue D, Chen C, 2022, Advances in Immunotherapy for Perioperative Non-Small Cell Lung Cancer in 2022. China Oncology Clinical, 49(23): 1236–1241.

Hong W, Liao X, Cai R, et al., 2024, Latest Advances in Perioperative Immunotherapy for Non-Small Cell Lung Cancer. Journal of Nanchang University (Medical Edition), 64(2): 88–94.

Fang Y, Su C, 2025, Research Progress in Immunotherapy for Non-Small Cell Lung Cancer in 2024. Electronic Journal of Comprehensive Oncology Treatment, 11(1): 44–49.

Hao Z, Yun D, Zhang Y, et al., 2024, Research Progress on Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Advances in Neoadjuvant Immunotherapy. Journal of Capital Medical University, 45(4): 666–677.

Xu Y, Mao F, Chen X, et al., 2026, Research Progress on Perioperative Immunotherapy for Non-Small Cell Lung Cancer. China Journal of Cardiothoracic Surgery, 33(2): 318–325.

Xie Q, Nian W, Zhang Y, 2022, Expert Discussion on Clinical Decision-Making for Perioperative Immunotherapy in Non-Small Cell Lung Cancer. Chongqing Medical Journal, 51(6): 901–909.

Liu X, Zhang G, Huang Y, et al., 2025, Hot Topics and Research Progress in Perioperative Immunotherapy for Non-Small Cell Lung Cancer. Journal of Clinical Surgery, 33(9): 938–942.

Wang C, Dai X, Xu S, et al., 2025, Clinical Research Status and Progress of Perioperative Immunotherapy for Early Resectable Non-Small Cell Lung Cancer. Chinese Journal of Cancer Prevention and Treatment, 32(15): 943–949, 960.

Ni J, Huang M, Zhang L, et al., 2021, Clinical Diagnosis and Treatment Recommendations for Adverse Reactions Related to Perioperative Immunotherapy in Non-Small Cell Lung Cancer. China Lung Cancer Journal, 24(3): 141–160.